Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Royalty Pharma Plc Cl A
(NQ:
RPRX
)
28.43
+0.23 (+0.83%)
Streaming Delayed Price
Updated: 2:15 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Royalty Pharma Plc Cl A
< Previous
1
2
Next >
Royalty Pharma Reports Second Quarter 2024 Results
August 08, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
July 24, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
July 19, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Third Quarter 2024 Dividend
July 17, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
June 03, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
May 28, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
May 22, 2024
From
Royalty Pharma plc; Cytokinetics
Via
GlobeNewswire
Royalty Pharma to Present at Upcoming Investor Conferences
May 13, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Reports First Quarter 2024 Results
May 09, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
May 09, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
April 19, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Second Quarter 2024 Dividend
April 17, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
February 28, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Reports Q4 and Full Year 2023 Results
February 15, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
January 30, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Dividend Increase
January 19, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
November 27, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
November 13, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
November 13, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Royalty Pharma Reports Third Quarter 2023 Results
November 08, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
October 19, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Declares Fourth Quarter 2023 Dividend
October 16, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023
October 11, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
September 21, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
September 05, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma to Present at Upcoming Investor Conferences
September 05, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)
August 24, 2023
From
Royalty Pharma plc
Via
GlobeNewswire
Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
August 24, 2023
From
Ferring Pharmaceuticals
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.